生长激素缺乏症患儿中相关心血管疾病标志物的研究进展

生长激素缺乏症(GHD)是指由垂体前叶合成和分泌释放的生长激素(GH)不足,或由于GH分子结构异常等所致的生长发育障碍性疾病。GHD不仅可导致身材矮小、生长缓慢,也可引起各种代谢紊乱。GHD患儿应用基因重组人生长激素(rhGH)治疗不仅能促进其线性生长,也会对相关的心血管疾病(CVD)标志物,如脂质谱、炎性介质、脂肪细胞因子、氧化应激物质、凝血-纤溶系统等生化指标、身体组分及心外膜脂肪组织厚度、颈动脉内膜中层厚度等超声指标产生影响,所有这些因素均参与动脉粥样硬化(AS)过程并可导致CVD的发生。人们对于rhGH的长期安全性问题一直存在争议,近年来,关于GHD患儿应用rhGH治疗前后相关CVD标志物变化的研究也备受关注。

Research progress on cardiovascular disease markers in children with growth hormone deficiency

Growth hormone deficiency (GHD) refers to the growth and developmental disorders caused by the lack of growth hormone (GH) released by the anterior lobe synthesis and secretion,or due to abnormal GH molecular structure.Treatment of recombinant human growth hormone (rhGH) in children with GHD not only promotes linear growth,but also affects related cardiovascular disease (CVD) markers such as lipid,inflammatory mediators,fats cytokines,oxidative stress substances,coagulation-fibrinolytic system and other biochemical indicators,body composition and epicardial adipose tissue thickness,carotid intima media thickness and other ultrasonic indicators,all of these factors are involved in atherosclerosis(AS) process and can lead to the occurrence of CVD.In recent years,studies on the changes of related CVD markers before and after rhGH treatment in children with GHD have also been of great concern in the long-term safety of rhGH.